Page 2491 - Williams Hematology ( PDFDrive )

2462 Index Index 2463

Mantle cell lymphoma (MCL) Marfan syndrome, 2061 storage pool shift, 1000
blastoid cell variant, 1653, 1654f Marginal neutrophil pool (MNP), 942t structure, 55–65
clinical features, 1654–1655, 1654t Marginal zone, spleen, 88–89 extracellular matrix, 61–64
course prognosis, 1655, 1655f, 1659 Marginal zone B-cell lymphomas, 1663–1668 hematopoietic cell organization and,
definition and history, 1653 definition and classification, 1595, 1663 64–65
differential diagnosis, 1543, 1655, 1667 epidemiology, 1663 hematopoietic niches, 56
epidemiology, 1571, 1653 extranodal. See Extranodal marginal zone innervation, 56
etiology and pathogenesis lymphoma of MALT type sinus architecture, 56–59, 57f, 58f, 59f
chromosomal abnormalities, laboratory features, 1595f vasculature, 55–56, 56f
1653–1654, 1654f nodal, 1495t, 1595, 1595f, 1667–1668, transplantation of. See Hematopoietic cell
t(11;14), 184t, 187, 224t, 1577, 1593, 1668f transplantation
1654f splenic, 1495t, 1557, 1558t, 1666–1667 Marrow blast crisis, 1465–1466
translocations, 187, 1494t Marginated pool, 941–942 Marrow examination, 27–37
gene mutations, 1653–1654, 1654f Margination, 280 in acute lymphoblastic leukemia,
ATM, 236t, 1654 Maribavir, for cytomegalovirus prophylaxis, 1510–1511
BCL1, 1494t 369–370 in acute myelogenous leukemia,
BIRC3, 237t Marrow 1381–1383, 1382f
CCND1, 236t, 1577 aging, 132–134, 133f, 136 in amyloidosis, 33
EZH2, 170 B-cell development in, 1151 in aplastic anemia, 519–520, 520f
gene expression, 1593–1594 cellularity, 31 aspiration technique for, 28–29, 28f
IGH, 236t, 1577 dendritic cell development in, 1151 in chronic myelogenous leukemia,
MEF2B, 236t drug-induced suppression, 553 1446–1447, 1446f
MLL2, 236t examination. See Marrow examination in clonal myeloid diseases, 1287
NOTCH1/2, 237t failure, in paroxysmal nocturnal in congenital dyserythropoietic anemia,
SOX11, 236t hemoglobinuria, 576–578, 576t type I, 565f
TLR2, 237t gelatinous transformation, 33 differential cell count, 32t
TP53, 236t, 1494t infections infiltrating, 33 in diffuse large B-cell lymphoma, 1627
TRAF2, 237t infiltration, 31–33, 657–659 in essential thrombocythemia, 1309f, 1310
WHSC1, 236t in amyloidosis, 33 flow cytometry for, 35–37, 36f
laboratory features clinical features, 658 in hairy cell leukemia, 1555, 1557f
histopathology, 1494t, 1593–1594, 1593f definition and history, 657 in hemochromatosis, 642
large bowel involvement, 1593, 1593f differential diagnosis, 659 history, 27, 53
small cell variant, 1653 etiology and pathogenesis, 657–658, in immune thrombocytopenia, 2003
therapy 658t indications for, 27
for advanced disease, 1655–1657, 1657t, fibrosis, 32 in infections, 33
1658t laboratory features, 658–659, 659f interpretation, 22f, 30–33, 32t, 33f
hematopoietic cell transplantation, 366 by malignant neoplasms, 31–32 iron stores, 34–35
for localized disease, 1655 in storage disorders, 33 in Langerhans cell histiocytosis, 1104
palbociclib, 218 therapy, course, prognosis, 659 in lymphomas, 31–32
recommendations, 1656f iron deficiency and, 633 macrophages, 1050f
for relapsed or recurrent disease, iron levels in, 635 in mastocytosis, 974–975, 975f
1658–1659, 1659t iron stain, 552–553 in megaloblastic anemia, 595, 595f
watchful waiting, 1655 lymphocyte differentiation in, 61 morphologic differentiation of
MAPIPA (monoclonal antibody-specific macrophage differentiation in, 61 hematopoietic lineages, 33–35
immobilization of platelet antigens) macrophages in, 1081–1082, 1082f myeloblasts, 927f
assay, 2000 microenvironment. See Hematopoietic in myelodysplastic syndromes, 1350f,
MAPK (mitogen-activated protein kinase), microenvironment 1353–1354
237, 266, 1054, 1055f, 1178, 1817 necrosis, 33, 657, 658f in myeloma, 31–32, 1715, 1741–1744,
Maraviroc, for graft-versus-host disease in acute myelogenous leukemia, 1385 1742f, 1743f, 1744f
prophylaxis, 371 in clonal myeloid diseases, 1287 needle biopsy technique for, 29
March hemoglobinuria, 631, 806 neutrophil kinetics, 940–941, 941t in pernicious anemia, 595f
MARCKS (myristoylated alanine-rich neutrophil reserves, 1000 polycythemia vera and, 1296
C-kinase substrate), 667, 668f precursor development in, 925, 926f in primary myelofibrosis, 1323f,
MARCO (macrophage receptor with reticulocytes, 482t 1326–1327
collagenous structure), 1055, 1057t, as source of hematopoietic stem cells for sample adequacy in, 30–31
1080, 1082, 1084, 1085f transplantation, 355, 356 in sideroblastic anemia, 916d

Kaushansky_index_p2393-2506.indd 2462 9/21/15 3:22 PM